ResMed Inc. (NYSE:RMD - Get Free Report) Director Jan De Witte sold 429 shares of the firm's stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $237.00, for a total value of $101,673.00. Following the sale, the director directly owned 3,772 shares of the company's stock, valued at $893,964. This represents a 10.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ResMed Stock Performance
Shares of ResMed stock traded up $5.22 on Wednesday, hitting $243.07. The stock had a trading volume of 1,218,307 shares, compared to its average volume of 1,309,701. The stock has a market cap of $34.19 billion, a price-to-earnings ratio of 22.14, a price-to-earnings-growth ratio of 1.45 and a beta of 0.77. The company has a quick ratio of 1.88, a current ratio of 2.65 and a debt-to-equity ratio of 0.04. ResMed Inc. has a twelve month low of $180.26 and a twelve month high of $277.67. The business's 50 day moving average is $232.74 and its two-hundred day moving average is $224.21.
ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.67 by $0.24. The business had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.39 billion. ResMed had a return on equity of 26.42% and a net margin of 27.79%. The firm's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.55 earnings per share. Analysts forecast that ResMed Inc. will post 12.14 EPS for the current year.
ResMed Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, November 12th will be issued a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, November 12th. ResMed's payout ratio is 24.04%.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the company. Wells Fargo & Company increased their price target on ResMed from $215.00 to $250.00 and gave the company an "equal weight" rating in a research note on Friday, October 30th. Royal Bank Of Canada boosted their price target on shares of ResMed from $262.00 to $288.00 and gave the stock an "outperform" rating in a research report on Friday, October 30th. Piper Sandler reduced their price objective on shares of ResMed from $233.00 to $225.00 and set a "neutral" rating on the stock in a research note on Friday, August 7th. Canaccord Genuity Group cut shares of ResMed from a "buy" rating to a "hold" rating in a research report on Monday, November 2nd. Finally, Citigroup lifted their target price on shares of ResMed from $240.00 to $270.00 and gave the stock a "neutral" rating in a research note on Friday, October 30th. Seven research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $253.69.
Read Our Latest Analysis on RMD
Institutional Trading of ResMed
Several large investors have recently made changes to their positions in the company. American Capital Management Inc. purchased a new position in shares of ResMed in the second quarter worth $44,522,000. BlackRock Inc. bought a new position in shares of ResMed during the 2nd quarter valued at about $2,400,375,000. Polymer Capital Management HK LTD purchased a new stake in shares of ResMed in the second quarter worth about $972,000. United Capital Financial Advisors LLC bought a new position in ResMed during the second quarter valued at approximately $1,105,000. Finally, Tidal Investments LLC boosted its stake in ResMed by 21.1% during the second quarter. Tidal Investments LLC now owns 32,332 shares of the medical equipment provider's stock valued at $6,301,000 after buying an additional 5,627 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.
ResMed Company Profile
(
Get Free Report)
ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ResMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list.
While ResMed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.